News Articles

Orphan Drug Designation Granted to Rezafungin in EU for the Treatment of Invasive Candidiasis CAMBRIDGE, U.K. & SAN DIEGO -Tuesday 26 January 2021

Invasive candidiasis (IC) is characterised as a severe, life-threatening Candida infection of the bloodstream and/or deep/visceral tissues1,2 Despite advances in antifungal therapy, IC is still an area of significant unmet patient need associated with high mortality, particularly in...

Julie Dehaene-Puype and Erik Nordkamp appointed as new regional Commercial Officers for Mundipharma -Tuesday 19 January 2021

(BUSINESS WIRE)-- FOR MEDICAL BUSINESS/INDUSTRY TRADE MEDIA ONLY The Mundipharma network of independently associated companies today announced two new appointments to their Executive Committee – Julie Dehaene-Puype as Chief Commercial Officer, Europe and Erik Nordkamp as Chief...

Laboratory Studies Confirm BETADINE® Antiseptic Products’ Effectiveness Against COVID-19 Virus -Friday 10 July 2020

(BUSINESS WIRE)-- Mundipharma today announced that laboratory testing at the Duke-NUS Medical School in Singapore, has confirmed the effectiveness of its BETADINE® antiseptic products against the novel coronavirus (SARS-CoV-2) which causes COVID-19 disease. Testing has demonstrated...

Marc Princen appointed new Global CEO for Mundipharma -Monday 15 June 2020

(BUSINESS WIRE)-- FOR MEDICAL BUSINESS/TRADE MEDIA ONLY Mundipharma announced today that Marc Princen has joined the Mundipharma network of independently associated companies as the Global Chief Executive Officer, effective June 1, 2020. In his new role, Princen will be responsible for all...

Evaluate BETADINE® Antiseptic Products’ Effectiveness Against SARS-CoV-2 -Thursday 23 April 2020

(BUSINESS WIRE)-- Mundipharma today announced that it will embark on an ambitious series of studies both in vitro and in vivo to evaluate the effectiveness of its BETADINE® antiseptic products against the novel coronavirus (SARS-CoV-2) which causes COVID-19 disease. Testing will be initiated in...

Mundipharma Enters Partnership With Samsung Bioepis to Expand Biosimilars Into Hong Kong and Taiwan -Friday 17 January 2020

(BUSINESS WIRE)-- Mundipharma today announced a partnership with Samsung Bioepis to commercialize Samsung Bioepis’ first-wave biosimilar candidates in Taiwan and Hong Kong. The partnership covers Samsung Bioepis’ biosimilar candidates in the field of immunology and oncology, including SB5...

Mundipharma EDO GmbH: US FDA grants Orphan Drug Designation for etoposide toniribate in relapsed/refractory biliary... -Friday 22 February 2019  

Biliary tract cancer or cholangiocarcinoma is rare, when patients fail first-line chemotherapy there are limited treatment options and in most cases the standard of care is palliative1,2 Etoposide toniribate is to be accelerated through a Phase III trial, with the aim of providing a...